ctDNA Could Serve as a Prognostic Tool in China for Predicting Outcomes in DLBCL

September 12, 2022Lisa AstorResults from a retrospective analysis presented during the 2022 ESMO Congress indicated that circulating tumor DNA could potentially be leveraged as a prognostic factor and

Updated on: October 24,2023 42

ctDNA Could Serve as a Prognostic Tool in China for Predicting Outcomes in DLBCL

September 12, 2022Lisa AstorResults from a retrospective analysis presented during the 2022 ESMO Congress indicated that circulating tumor DNA could potentially be leveraged as a prognostic factor and

Updated on:October 24,2023 42

Sunitinib Elicits Improved Efficacy Vs Placebo in Malignant Pheochromocytoma/Paragangliomas

September 20, 2021Kristie L. KahlFirst-line sunitinib was found to improve efficacy compared with placebo in patients with malignant pheochromocytoma and paragangliomas.First-line sunitinib (Sut

Updated on: October 24,2023 32

Sunitinib Elicits Improved Efficacy Vs Placebo in Malignant Pheochromocytoma/Paragangliomas

September 20, 2021Kristie L. KahlFirst-line sunitinib was found to improve efficacy compared with placebo in patients with malignant pheochromocytoma and paragangliomas.First-line sunitinib (Sut

Updated on:October 24,2023 32

Trabectedin/Durvalumab Shows Early Activity, Demonstrates Feasibility for Soft Tissue Sarcoma

September 21, 2020Nichole Tuckerhe feasibility of treatment with trabectedin in combination with durvalumab as treatment of patients with advanced or metastatic pretreated soft tissue sarcoma was demo

Updated on: October 24,2023 33

Trabectedin/Durvalumab Shows Early Activity, Demonstrates Feasibility for Soft Tissue Sarcoma

September 21, 2020Nichole Tuckerhe feasibility of treatment with trabectedin in combination with durvalumab as treatment of patients with advanced or metastatic pretreated soft tissue sarcoma was demo

Updated on:October 24,2023 33

NXC-201 Demonstrates Feasibility of BCMA-Directed CAR T-Cell Therapy in Relapsed/Refractory AL

September 30, 2023Ryan Scotthe novel anti-BCMA CAR T-cell therapy NXC-201 displayed safety and elicited hematologic and organ responses in patients with relapsed/refractory amyloid light chain amyloid

Updated on: October 24,2023 267

NXC-201 Demonstrates Feasibility of BCMA-Directed CAR T-Cell Therapy in Relapsed/Refractory AL

September 30, 2023Ryan Scotthe novel anti-BCMA CAR T-cell therapy NXC-201 displayed safety and elicited hematologic and organ responses in patients with relapsed/refractory amyloid light chain amyloid

Updated on:October 24,2023 267

Pre- and post-surgical immunotherapy improves outcomes for patients with operable lung cancer

byUniversity of Texas M. D. Anderson Cancer CenterCredit: Pixabay/CC0 Public DomainCompared with pre-surgical (neoadjuvant) chemotherapy alone, adding perioperative immunotherapy—given before an

Updated on: October 23,2023 243

Pre- and post-surgical immunotherapy improves outcomes for patients with operable lung cancer

byUniversity of Texas M. D. Anderson Cancer CenterCredit: Pixabay/CC0 Public DomainCompared with pre-surgical (neoadjuvant) chemotherapy alone, adding perioperative immunotherapy—given before an

Updated on:October 23,2023 243

Adding immunotherapy to chemotherapy regimen improves survival in metastatic bladder cancer patients

byThe Mount Sinai HospitalCredit: Unsplash/CC0 Public DomainA clinical trial co-led by Mount Sinai researchers is the first to show that using chemotherapy with immunotherapy resulted in improve

Updated on: October 23,2023 164

Adding immunotherapy to chemotherapy regimen improves survival in metastatic bladder cancer patients

byThe Mount Sinai HospitalCredit: Unsplash/CC0 Public DomainA clinical trial co-led by Mount Sinai researchers is the first to show that using chemotherapy with immunotherapy resulted in improve

Updated on:October 23,2023 164

suggest better use of existing drugs increases cervical cancer survival and reduces recurrence

byUniversity College LondonCredit: Unsplash/CC0 Public DomainThe INTERLACE phase III trial assessed whether a short course of induction chemotherapy (IC) prior to chemoradiation (CRT) could redu

Updated on: October 23,2023 293

suggest better use of existing drugs increases cervical cancer survival and reduces recurrence

byUniversity College LondonCredit: Unsplash/CC0 Public DomainThe INTERLACE phase III trial assessed whether a short course of induction chemotherapy (IC) prior to chemoradiation (CRT) could redu

Updated on:October 23,2023 293

Dual-action drug produces positive results in patients with advanced neuroendocrine tumors

byDana-Farber Cancer InstituteCredit: Pixabay/CC0 Public DomainA drug that simultaneously strikes cancer cells' growth circuits and pipeline to the bloodstream produced encouraging results i

Updated on: October 23,2023 33

Dual-action drug produces positive results in patients with advanced neuroendocrine tumors

byDana-Farber Cancer InstituteCredit: Pixabay/CC0 Public DomainA drug that simultaneously strikes cancer cells' growth circuits and pipeline to the bloodstream produced encouraging results i

Updated on:October 23,2023 33

Belzutifan outperforms everolimus in advanced kidney cancer treatment

byDana-Farber Cancer InstituteCredit: CC0 Public DomainBelzutifan significantly reduced the risk of progression of clear cell renal cell carcinoma (ccRCC), the most common type of kidney cancer,

Updated on: October 23,2023 264

Belzutifan outperforms everolimus in advanced kidney cancer treatment

byDana-Farber Cancer InstituteCredit: CC0 Public DomainBelzutifan significantly reduced the risk of progression of clear cell renal cell carcinoma (ccRCC), the most common type of kidney cancer,

Updated on:October 23,2023 264

Tumor Profiling Studies Illuminate Nuances Across Malignancies

November 21, 2022Megan HollaschMolecular and immune landscapes for solid tumors are constantly evolving as precision medicine techniques become more sensitive and next-generation sequencing methods ar

Updated on: October 17,2023 205

Tumor Profiling Studies Illuminate Nuances Across Malignancies

November 21, 2022Megan HollaschMolecular and immune landscapes for solid tumors are constantly evolving as precision medicine techniques become more sensitive and next-generation sequencing methods ar

Updated on:October 17,2023 205

Frontline Eganelisib Triplet Provides Potential Long-term PFS Benefit in Metastatic TNBC

November 15, 2022Kristi RosaThe addition of eganelisib to atezolizumab and nab-paclitaxel demonstrated evidence of a long-term progression-free survival benefit when used as first-line treatment in pa

Updated on: October 17,2023 290

Frontline Eganelisib Triplet Provides Potential Long-term PFS Benefit in Metastatic TNBC

November 15, 2022Kristi RosaThe addition of eganelisib to atezolizumab and nab-paclitaxel demonstrated evidence of a long-term progression-free survival benefit when used as first-line treatment in pa

Updated on:October 17,2023 290

CYNK-101 Plus Avelumab Mediates ADCC Activity in Select PD-L1+ Solid Tumors

November 13, 2022Gina MauroCYNK-101 demonstrated synergistic activity when used in combination with avelumab through antibody-dependent cellular cytotoxicity against PD-L1–positive non–small cell lung

Updated on: October 17,2023 129

CYNK-101 Plus Avelumab Mediates ADCC Activity in Select PD-L1+ Solid Tumors

November 13, 2022Gina MauroCYNK-101 demonstrated synergistic activity when used in combination with avelumab through antibody-dependent cellular cytotoxicity against PD-L1–positive non–small cell lung

Updated on:October 17,2023 129